Literature DB >> 2911023

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.

D T Dexter1, C J Carter, F R Wells, F Javoy-Agid, Y Agid, A Lees, P Jenner, C D Marsden.   

Abstract

Polyunsaturated fatty acid (PUFA) levels (an index of the amount of substrate available for lipid peroxidation) were measured in several brain regions from patients who died with Parkinson's disease and age-matched control human postmortem brains. PUFA levels were reduced in parkinsonian substantia nigra compared to other brain regions and to control tissue. However, basal malondialdehyde (MDA; an intermediate in the lipid peroxidation process) levels were increased in parkinsonian nigra compared with other parkinsonian brain regions and control tissue. Expressing basal MDA levels in terms of PUFA content, the difference between parkinsonian and control substantia nigra was even more pronounced. Stimulating MDA production by incubating tissue with FeSO4 plus ascorbic acid, FeSO4 plus H2O2, or air alone produced lower MDA levels in the parkinsonian substantia nigra, probably reflecting the lower PUFA content. These results may indicate that an increased level of lipid peroxidation continues to occur in the parkinsonian nigra up to the time of death, perhaps because of continued exposure to excess free radicals derived from some endogenous or exogenous neurotoxic species.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2911023     DOI: 10.1111/j.1471-4159.1989.tb09133.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  270 in total

Review 1.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 2.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

3.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 4.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 5.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

6.  Lipid peroxidation as the mechanism of modification of the affinity of the Na+, K+-ATPase active sites for ATP, K+, Na+, and strophanthidin in vitro.

Authors:  O P Mishra; M Delivoria-Papadopoulos; G Cahillane; L C Wagerle
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

7.  Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study.

Authors:  Jirasak Wong-Ekkabut; Zhitao Xu; Wannapong Triampo; I-Ming Tang; D Peter Tieleman; Luca Monticelli
Journal:  Biophys J       Date:  2007-08-31       Impact factor: 4.033

Review 8.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 9.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Oxidation of survival factor MEF2D in neuronal death and Parkinson's disease.

Authors:  Li Gao; Hua She; Wenming Li; Jin Zeng; Jinqiu Zhu; Dean P Jones; Zixu Mao; Guodong Gao; Qian Yang
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.